Exelixis
EXEL
#1696
Rank
$9.90 B
Marketcap
$34.69
Share price
-3.83%
Change (1 day)
48.63%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.28

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.28. In 2022 the company made an earnings per share (EPS) of $0.57 a decrease over its 2021 EPS that were of $0.74.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.28-50.3%
2022$0.57-22.97%
2021$0.74100%
2020$0.37-65.09%
2019$1.06-53.91%
2018$2.30333.96%
2017$0.53-260.61%
2016-$0.33-58.75%
2015-$0.80-42.45%
2014-$1.395.3%
2013-$1.3243.48%
2012-$0.92-264.29%
2011$0.56-165.88%
2010-$0.85-32.54%
2009-$1.26-17.65%
2008-$1.5375.86%
2007-$0.87-25.64%
2006-$1.178.33%
2005-$1.08-42.86%
2004-$1.8930.34%
2003-$1.45-5.23%
2002-$1.53-0.65%
2001-$1.54-51.88%
2000-$3.20

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.50 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$3.18 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$1.82 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.97 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$14.15 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$14.09 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$1.86 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$10.00-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.84-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA